Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection

Study Overview
=================
Brief Summary
-----------------
Compare the quality of life at 6 months between 2 populations of patients followed for terminal ileitis of Crohn's disease treated with anti-TNF or ileocecal resection.

Detailed Description
-----------------
Two groups of patients suffering from Crohn's terminal ileitis will be matched by sex, age (A2, A3), the time evolution of the disease, the length of the diseased ileal segment (less than 10 cm; 10 to 30; 30 to 50 cm) and the Montreal classification (B1, B2). The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time. The surgical group are the patients operated on for the first time by means of ileocecal resection by laparoscopy or laparotomy without any severity criteria or perianal lesions and do not require prophylactic treatment of recurrence.

Official Title
-----------------
Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Drug: Anti TNF
* Procedure: ileocecal resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: isolated Crohn's ileitis without history of bowel resection and never previously been treated with anti-TNF Men and woman over 18 years Patient with social security cover reapproved indication during multidisciplinary meeting Patient able to receive clear information in written and oral Informed consent signed by the patient Exclusion Criteria: Prophylactic treatment of recurrence before endoscopic control at the 6th postoperative month. Contraindication to Anti-TNF after the initial lap works. The side effects of surgery or anti-TNF are not exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: medical treatment by Anti TNF<br>The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time | Drug: Anti TNF<br>* Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.<br>|
| Active Comparator: ileocecal resection<br>The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy | Procedure: ileocecal resection<br>* The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life (QoL) by Inflammatory Bowel Disease Questionnaire | comparing the quality of life (QoL) by Inflammatory Bowel Disease Questionnaire (IBDQ) at 6 months between 2 populations of patients followed for Crohn's terminal ileitis treated with anti-TNF or operated on by means of ileocecal resection | at 6 months from the beginning of medical treatment or surgical resection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory Bowel Disease Questionnaire (IBDQ) | Inflammatory Bowel Disease Questionnaire (IBDQ) at 6 months between 2 populations of patient | at baseline (beginning of medical treatment or surgical resection), at 6 months | 
| Crohn's disease activity index (CDAI) |  | at baseline, at 6 months | 
| Length of small intestine segment resection | Length of small intestine segment <10 cm 10 to 30 cm 30 to 50 cm | at baseline | 
| Duration of hospital stay |  | at baseline | 
| Clavien-Dindo classification of surgical complications |  | at baseline, at 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of life, Crohn's disease, Ileocecal resection, Anti TNF